Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer

CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer

(2018) J Smeby et al.   ANNALS OF ONCOLOGY

The value of additional bevacizumab in patients with high-risk stroma-high colon cancer. A study within the QUASAR2 trial, an open-label randomized phase 3 trial

(2018) Anouck Huijbers et al.   JOURNAL OF SURGICAL ONCOLOGY

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

(2018) Franck Pagès et al.   LANCET

Prognostic Effect of Tumor Sidedness in Colorectal Cancer: A SEER-Based Analysis

(2018) Yaqi Li et al.   Clinical Colorectal Cancer

Circulating Tumor DNA–Defined Minimal Residual Disease in Solid Tumors: Opportunities to Accelerate the Development of Adjuvant Therapies

(2018) Arvind Dasari et al.   JOURNAL OF CLINICAL ONCOLOGY

The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors

(2017) Laetitia Marisa et al.   JNCI-Journal of the National Cancer Institute

The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors

(2017) Laetitia Marisa et al.   JNCI-Journal of the National Cancer Institute

Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy

(2016) Etienne Becht et al.   CLINICAL CANCER RESEARCH

Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability

(2016) Bernhard Mlecnik et al.   IMMUNITY

The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis

(2016) Bernhard Mlecnik et al.   Science Translational Medicine

Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes

(2016) Nan Song et al.   JAMA Oncology

Personalizing Colon Cancer Adjuvant Therapy: Selecting Optimal Treatments for Individual Patients

(2015) Rodrigo Dienstmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Stromal gene expression defines poor-prognosis subtypes in colorectal cancer

(2015) Alexandre Calon et al.   NATURE GENETICS

The consensus molecular subtypes of colorectal cancer

(2015) Justin Guinney et al.   NATURE MEDICINE

A 5-gene classifier from the carcinoma-associated fibroblast transcriptomic profile and clinical outcome in colorectal cancer

(2015) Mireia Berdiel-Acer et al.   Oncotarget

Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012

(2013) J. Ferlay et al.   EUROPEAN JOURNAL OF CANCER

Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition

(2013) Paul Roepman et al.   INTERNATIONAL JOURNAL OF CANCER

T cell responses against microsatellite instability-induced frameshift peptides and influence of regulatory T cells in colorectal cancer

(2012) Kathrin Bauer et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

Histopathologic-Based Prognostic Factors of Colorectal Cancers Are Associated With the State of the Local Immune Reaction

(2011) Bernhard Mlecnik et al.   JOURNAL OF CLINICAL ONCOLOGY